AstraZeneca aims for revenue doubling by 2030

AstraZeneca has reached a significant milestone, with its market capitalisation surpassing £200 billion for the first time, solidifying its position as the most valuable company listed on the London Stock Exchange. This achievement marks a pivotal moment for the Cambridge-based pharmaceuticals giant, which has seen its stock performance steadily rise in recent months. The surge in AstraZeneca's share price follows a successful investor event held in May, where the company outlined ambitious plans to nearly double its revenues to $80 billion by 2030. This strategic vision is part of what the company describes as a “new era of growth,” aimed at expanding its market presence and enhancing shareholder value. On the trading front, AstraZeneca's shares closed up 1.1 percent, or 140 pence, reaching £129.20. This increase in share value propelled the company's overall valuation to just under £200.3 billion, reflecting strong investor confidence in its future prospects and growth strategy. Under the leadership of CEO Sir Pascal Soriot, AstraZeneca continues to innovate and expand its portfolio, positioning itself as a leader in the pharmaceutical industry. The crossing of the £200 billion threshold not only highlights the company's financial strength but also underscores its pivotal role in the global healthcare landscape.